{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"dataset_type":["N/A"],"full_dataset_link":["https://ega-archive.org/datasets/EGAD00001006585"],"sample_count":["30"],"description":["EGA dataset EGAD00001006585"],"repository":["EGA"],"title":["Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase III clinical trial"],"additional_accession":[]},"is_claimable":false,"name":"93451a52-efd0-40f7-a5ca-f6e94d159857 - samples","description":"In our study, we hypothetyzed that CD34progenitors from cases with undetectable Minimal residual Disease (MRD) by flow cytometry  would contain cells with leukemic-initiating-potential that could be identified on genetic (rather than phenotypic) grounds by Whole Exome Sequencing.","dates":{"updated":"2020-11-25 08:35:12"},"accession":"EGAD00001006585","cross_references":{"TAXONOMY":["9606"],"EGA":["EGAC00001001806","EGAS00001004574"]}}